QDEL1 Stock Chart & Stats
$570.28
$0.00(0.00%)
At close: 4:00 PM EDT
$570.28
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$570.28 - $570.28
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$14.14B
Enterprise Value$3.89K
Total Cash (Recent Filing)$123.40M
Total Debt (Recent Filing)$3.08B
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Nov 04, 2026EPS Estimate
3.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.44
Shares Outstanding68,575,424
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$254.55Price Target Upside-55.36% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)13.1
Revenue Forecast (FY)$43.12B
Bulls Say, Bears Say
Bulls Say
Ex-China Growth And DiversificationBroad growth across major franchises and regions outside China indicates resilient underlying demand and reduces reliance on any single market. Continued expansion in laboratories, immunohematology, and point-of-care testing can support a more diversified revenue base over the next several quarters.
EBITDA Margin ExpansionStrong adjusted EBITDA growth and meaningful margin expansion show that operating discipline is beginning to improve earnings conversion despite a seasonally weak quarter. If maintained, better cost absorption and productivity can strengthen profitability and support investment in commercial growth.
Lex And Neulixa CommercializationThe Lex acquisition adds a product commercialization opportunity to QuidelOrtho’s existing diagnostics portfolio. Progress toward manufacturing readiness, customer placements, and utilization could broaden the respiratory offering and create an additional source of recurring test demand.
Bears Say
China Pricing UncertaintyProposed IVD pricing changes have already reduced customer purchasing and inventory levels in China, while the broader pilot remains unresolved. Persistent regulatory uncertainty can pressure revenue visibility, pricing, and geographic mix until customers regain confidence in procurement decisions.
Negative Cash GenerationRecent cash consumption means the business is not currently funding operations and investment internally, increasing the importance of working-capital improvement and execution. Withdrawal of free-cash-flow guidance further reduces visibility into deleveraging capacity over the coming quarters.
Weak Profitability And Revenue OutlookDeep losses combined with limited recent revenue growth indicate that the current cost structure remains too heavy relative to sales. Sustained negative EBIT and EBITDA margins could constrain reinvestment, delay balance-sheet repair, and make recovery dependent on successful operational execution.
QuidelOrtho News
QDEL1 FAQ
What was QuidelOrtho’s price range in the past 12 months?
QuidelOrtho lowest stock price was $570.28 and its highest was $570.28 in the past 12 months.
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is $14.14B.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Nov 04, 2026 which is in 52 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on Aug 06, 2026. The company reported $2.2 earnings per share for the quarter, beating the consensus estimate of -$0.829 by $3.029.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Overvalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is 3.42.
How many shares outstanding does QuidelOrtho have?
QuidelOrtho has 68,575,424 shares outstanding.
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of $2.2 in its last earnings report, beating expectations of -$0.829. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in MX:QDEL1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$254.55 (-55.36% Downside)
$254.55 (-55.36% Downside)
Blogger Sentiment
Neutral
MX:QDEL1 Sentiment 60%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL1 Company Deck
QDEL1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all MX:QDEL1 earnings summariesQDEL1 Stock 12 Month Forecast
Average Price Target
$254.55
▼(-55.36% Downside)